CVS Stock Surges 7.6% With A 5-day Winning Spree On Record Revenue Beat
CVS Health (CVS) – a provider of pharmacy benefit management and retail health products – hit 5-day winning streak, with cumulative gains over this period amounting to a 7.6%. The company market cap has surged by about $7.5 Bil over the last 5 days, and currently stands at $106 Bil.
The stock has YTD (year-to-date) return of 6.6% compared to 1.5% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Rally?
[1] Sustained Institutional Accumulation
- Last quarter revenue of $102.87B beat estimates
- Consensus analyst rating of ‘Moderate Buy’
- Impact: Bullish moving average trend, Increased investor confidence
Opportunity or Trap?
Below is our take on valuation.
There are several things to fear in CVS stock given its overall Weak operating performance and financial condition. Hence, despite its Low valuation, this makes the stock look Risky (For details, see Buy or Sell CVS).
But here is the real interesting point.
You are reading about this 7.6% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
Returns vs S&P 500
The following table summarizes the return for CVS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CVS | S&P 500 |
|---|---|---|
| 1D | 1.0% | 0.5% |
| 5D (Current Streak) | 7.6% | 0.1% |
| 1M (21D) | 8.4% | 0.6% |
| 3M (63D) | 4.3% | 3.1% |
| YTD 2026 | 6.6% | 1.5% |
| 2025 | 84.3% | 16.4% |
| 2024 | -40.8% | 23.3% |
| 2023 | -12.5% | 24.2% |
However, big gains can follow sharp reversals – but how has CVS behaved after prior drops? See CVS Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 65 S&P constituents with 3 days or more of consecutive gains and 42 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 17 | 37 |
| 4D | 35 | 0 |
| 5D | 9 | 4 |
| 6D | 3 | 0 |
| 7D or more | 1 | 1 |
| Total >=3 D | 65 | 42 |
Key Financials for CVS Health (CVS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $357.8 Bil | $372.8 Bil |
| Operating Income | $14.6 Bil | $9.8 Bil |
| Net Income | $8.3 Bil | $4.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $98.9 Bil | $102.9 Bil |
| Operating Income | $2.4 Bil | $2.5 Bil |
| Net Income | $1.0 Bil | $-4.0 Bil |
While CVS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.